CMN Weekly (25 October 2024) - Your Weekly CRISPR...
CMN Weekly
Oct. 25, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Moonwalk Biosciences
Company Type: Therapeutic development
Main focus: Developing new therapeutics by targeting the epigenome
Company stage: Pre-clinical
Diseases: not disclosed
Genome-editing tool: CRISPR
Funding stage: Series A
Location: South San Francisco, California, USA
Website: https://moonwalk.bio/
Pipeline:
Partners:
Moonwalk Biosciences is the first company to couple an epigenetic discovery platform with precise engineering to develop epigenetic therapeutics. Using advanced AI-based prediction of epigenetic targets and CRISPR-based precision technology, Moonwalk Biosciences aims to develop therapies to reprogramme cells to their healthy state. Moonwalk Bioscience’s focus on epigenetic engineering allows for a read-and-write technology with the potential to treat diseases at their root cause.
